Jove
Visualize
Contact Us

Related Concept Videos

EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

2.8K
Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
2.8K
Urea Cycle01:23

Urea Cycle

45.6K
The urea cycle describes how liver cells convert ammonia to urea. Ammonia is a toxic waste product of protein catabolism. Land animals must convert ammonia into the less toxic urea which can be safely eliminated by the kidneys through urine. Marine animals excrete ammonia directly, and the surrounding water dilutes the ammonia to safe levels.
45.6K
iPS Cell Differentiation01:22

iPS Cell Differentiation

2.8K
The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
2.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Safety and efficacy analysis of in vivo lentiviral gene therapy in pre-clinical ARC syndrome models.

Nature communications·2026
Same author

Delivering the Message: Translating mRNA Therapy for Liver Inherited Metabolic Diseases.

Journal of inherited metabolic disease·2025
Same author

Macrophage Inhibitor Clodronate Enhances Liver Transduction of Lentiviral but Not Adeno-Associated Viral Vectors or mRNA Lipid Nanoparticles in Neonatal and Juvenile Mice.

Cells·2024
Same author

mRNA therapy corrects defective glutathione metabolism and restores ureagenesis in preclinical argininosuccinic aciduria.

Science translational medicine·2024
Same author

The incidence of movement disorder increases with age and contrasts with subtle and limited neuroimaging abnormalities in argininosuccinic aciduria.

Journal of inherited metabolic disease·2023
Same author

Prolonged respiratory failure responds to conventional therapy in isolated homocysteine remethylation defects.

JIMD reports·2023
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Video

Updated: Aug 27, 2025

Generation of Induced Pluripotent Stem Cells from Muscular Dystrophy Patients: Efficient Integration-free Reprogramming of Urine Derived Cells
09:11

Generation of Induced Pluripotent Stem Cells from Muscular Dystrophy Patients: Efficient Integration-free Reprogramming of Urine Derived Cells

Published on: January 28, 2015

11.4K

Modelling urea cycle disorders using iPSCs.

Claire Duff1, Julien Baruteau2,3,4

  • 1Genetics and Genomic Medicine Department, Great Ormond Street Institute of Child Health, University College London, London, UK.

NPJ Regenerative Medicine
|September 26, 2022
PubMed
Summary
This summary is machine-generated.

Urea cycle disorders (UCDs) are serious inherited metabolic diseases. Induced pluripotent stem cells (iPSCs) offer a promising new way to model UCDs for developing innovative therapies.

More Related Videos

Author Spotlight: Optimizing iPSC Differentiation for Efficient Production to Generate Kidney Organoids
07:22

Author Spotlight: Optimizing iPSC Differentiation for Efficient Production to Generate Kidney Organoids

Published on: September 1, 2023

2.8K
Generation of Human Brain Organoids for Mitochondrial Disease Modeling
08:09

Generation of Human Brain Organoids for Mitochondrial Disease Modeling

Published on: June 21, 2021

6.3K

Related Experiment Videos

Last Updated: Aug 27, 2025

Generation of Induced Pluripotent Stem Cells from Muscular Dystrophy Patients: Efficient Integration-free Reprogramming of Urine Derived Cells
09:11

Generation of Induced Pluripotent Stem Cells from Muscular Dystrophy Patients: Efficient Integration-free Reprogramming of Urine Derived Cells

Published on: January 28, 2015

11.4K
Author Spotlight: Optimizing iPSC Differentiation for Efficient Production to Generate Kidney Organoids
07:22

Author Spotlight: Optimizing iPSC Differentiation for Efficient Production to Generate Kidney Organoids

Published on: September 1, 2023

2.8K
Generation of Human Brain Organoids for Mitochondrial Disease Modeling
08:09

Generation of Human Brain Organoids for Mitochondrial Disease Modeling

Published on: June 21, 2021

6.3K

Area of Science:

  • Biochemistry
  • Genetics
  • Regenerative Medicine

Background:

  • The urea cycle is crucial for nitrogen waste disposal in the liver.
  • Urea cycle disorders (UCDs) are inherited metabolic diseases affecting 1 in 35,000 live births, leading to hyperammonaemia, high mortality, and neurological damage.
  • Current treatments include diet modification, ammonia scavengers, and liver transplantation, highlighting a need for novel therapeutic strategies.

Purpose of the Study:

  • To review the progress in developing induced pluripotent stem cell (iPSC) models for UCDs.
  • To discuss the challenges and future potential of iPSC-based disease modeling for UCDs.
  • To explore iPSCs as a platform for discovering new therapeutics for UCDs.

Main Methods:

  • Utilizing induced pluripotent stem cells (iPSCs) for disease modeling.
  • Employing genome editing technologies to create patient-specific models.
  • Generating both 2D and 3D iPSC-based models for UCDs.

Main Results:

  • iPSCs combined with genome editing enable the creation of patient-specific 'avatar' models in vitro.
  • These models facilitate the investigation of UCD pathophysiology and the identification of therapeutic targets.
  • Progress has been made in generating 2D and 3D iPSC models for UCDs.

Conclusions:

  • iPSC technology offers a powerful tool for modeling UCDs and understanding their mechanisms.
  • Patient-specific iPSC models provide a platform for drug discovery and development of next-generation therapies.
  • Further innovation in iPSC-based modeling holds significant promise for treating UCDs.